Merck Stock Holds Steady Despite Analyst Price Target Cuts
Cantor Fitzgerald has reaffirmed its Neutral rating on Merck & Co. stock, with a price target of $120.00.
The firm highlighted the significance of INTerpath-001, which is set to be a major event at ESMO following the early stoppage of the study in adjuvant melanoma due to its overwhelming efficacy.
Cantor Fitzgerald noted that Merck shares have added more than $40 billion in market capitalization, with meaningful credit given to the company's efforts beyond melanoma. The stock currently trades at $149.50, near its 52-week high of $156.92, reflecting a remarkable 91% return over the past year.
According to InvestingPro analysis, Merck appears slightly overvalued relative to its Fair Value. Investors can access comprehensive analysis through Merck's Pro Research Report, one of 1,400+ available on the platform.